Last reviewed · How we verify
LABA/LAMA or Placebo inhalation
LABA/LAMA combination provides dual bronchodilation by stimulating beta-2 adrenergic receptors (LABA) and blocking muscarinic M3 receptors (LAMA) to relax airway smooth muscle.
LABA/LAMA combination provides dual bronchodilation by stimulating beta-2 adrenergic receptors (LABA) and blocking muscarinic M3 receptors (LAMA) to relax airway smooth muscle. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Asthma maintenance therapy (LAMA/LABA combinations).
At a glance
| Generic name | LABA/LAMA or Placebo inhalation |
|---|---|
| Also known as | Inhaled dual Bronchodilator |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Drug class | LABA/LAMA combination bronchodilator |
| Target | Beta-2 adrenergic receptor and muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Long-acting beta-2 agonists (LABA) increase intracellular cAMP to promote airway smooth muscle relaxation, while long-acting muscarinic antagonists (LAMA) block acetylcholine-mediated bronchoconstriction. Together, these complementary mechanisms provide sustained bronchodilation over 24 hours, improving airflow and reducing symptoms in obstructive airway diseases.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Asthma maintenance therapy (LAMA/LABA combinations)
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Nasopharyngitis
Key clinical trials
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (PHASE3)
- Evaluation of Dupilumab in Children With Uncontrolled Asthma (PHASE3)
- Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation (PHASE4)
- Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects (PHASE1)
- Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb) (PHASE2)
- Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks (PHASE3)
- Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: